Amgen and AstraZeneca’s psoriasis drug beats blockbuster Stelara in head-to-head trial

John Carroll

and its Big Pharma partner AstraZeneca have roped in another round of promising Phase III plaque data for their IL-17 contender brodalumab, which beat Johnson & Johnson's big earner in a head-to-head study.

FierceBiotech News

Share This Post

Related Articles

Leave a Reply

© 2018 Global Regulatory Science. All rights reserved. Site Admin · Entries RSS · Comments RSS